Login to Your Account



Celiac Disease 'Landmark' Phase II

Alvine and Dandy: Option Deal Brings $70M AbbVie Up Front

By Randy Osborne
Staff Writer

Wednesday, May 15, 2013
AbbVie Inc.'s $70 million up front buys an option to acquire Alvine Pharmaceuticals Inc.'s drug candidate for celiac disease or the company itself, after Phase IIb trials are finished with ALV003, a two-enzyme combo that degrades gluten.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription